RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic"

Bryan Oronsky; Corey A Carter; Scott Caroen; Curtis Scribner; Arnold Oronsky; Tony R Reid

doi:10.1080/2162402X.2020.1746172

RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic"

Oncoimmunology. 2020 Apr 3;9(1):1746172. doi: 10.1080/2162402X.2020.1746172.

Authors

Bryan Oronsky¹, Corey A Carter¹, Scott Caroen¹, Curtis Scribner¹, Arnold Oronsky², Tony R Reid¹

Affiliations

¹ Clinical and Scientific Department, EpicentRx, Inc, La Jolla, CA, USA.
² Clinical and Scientific Department, InterWest Partners, Menlo Park, CA, USA.

Abstract

The main mechanism of action of RRx-001, a pharmaceutically unprecedented sui generis Phase 3 small molecule that is derived from the aerospace industry, is clarified. RRx-001 has demonstrated anticancer activity through antiangiogenic, immune, epigenetic, antioxidant, apoptotic and nitric oxide (NO) pathways, resulting in its pleiomorphic description as an antiangiogenic/vascular normalizer.

Keywords: CD47; Immunotherapy; MYC; erythrophagoimmunotherapeutic; hemoglobin; small molecule; tumor associated macrophage.

MeSH terms

Azetidines*
CD47 Antigen*
Nitro Compounds

Substances

Azetidines
CD47 Antigen
Nitro Compounds
RRx-001